Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. (SLNO) Revenue
Annual & quarterly revenue history · segment & region breakdown
SLNO · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsSoleno Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.29B, an increase of 0.00% year-over-year from $0.19B in FY2025.
Revenue trend
2025 – 2012 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.19B | +$0.19B | — |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$1.55B | — |
| 2017-12-31 | $-1.55B | -$1.55B | -107145.41% |
| 2016-12-31 | $0.00B | +$0.00B | +274.34% |
Compare revenue vs peers
BiotechnologyCompare SLNO revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Soleno Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Soleno Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Soleno Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
SLNO revenue · 4 questionsSLNO's trailing twelve-month (TTM) revenue is $0.29B. That is an increase of 0.00% year-over-year from $0.19B in FY2025.
▸ Source: FMP · Soleno Therapeutics, Inc. SEC filings · GAAP · Soleno Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026